BIOAGE LABS, INC. Comprehensive Income
BIOAGE LABS, INC. (BIOA) reported Comprehensive Income of -$26.65 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-05
- BIOAGE LABS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$26.65M.
- BIOAGE LABS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$22.46M.
- BIOAGE LABS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$25.94M.
- BIOAGE LABS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$20.11M.
- BIOAGE LABS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$80.57M.
- BIOAGE LABS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$71.03M.
- BIOAGE LABS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$63.86M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$26.65M 10-Q · filed 2026-08-05 | -$49.11M 10-Q · filed 2026-08-05 | -$75.05M derived: sum of 3 quarters · filed 2026-08-05 | -$95.15M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$22.46M 10-Q · filed 2026-05-08 | -$48.40M derived: sum of 2 quarters · filed 2026-05-08 | -$68.51M derived: sum of 3 quarters · filed 2026-05-08 | -$90.12M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$25.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$46.05M derived: sum of 2 quarters · filed 2026-03-24 | -$67.66M derived: sum of 3 quarters · filed 2026-08-05 | -$80.57M 10-K · filed 2026-03-24 |
| 2025-09-30 | -$20.11M 10-Q · filed 2025-11-06 | -$41.72M derived: sum of 2 quarters · filed 2026-08-05 | -$54.63M 10-Q · filed 2025-11-06 | -$75.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$21.61M 10-Q · filed 2026-08-05 | -$34.52M 10-Q · filed 2026-08-05 | -$55.63M derived: sum of 3 quarters · filed 2026-08-05 | -$78.98M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$12.91M 10-Q · filed 2026-05-08 | -$34.01M derived: sum of 2 quarters · filed 2026-05-08 | -$57.36M derived: sum of 3 quarters · filed 2026-05-08 | -$70.96M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$21.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$44.45M derived: sum of 2 quarters · filed 2026-03-24 | -$58.05M derived: sum of 3 quarters · filed 2026-03-24 | -$71.03M 10-K · filed 2026-03-24 |
| 2024-09-30 | -$23.35M 10-Q · filed 2025-11-06 | -$36.95M derived: sum of 2 quarters · filed 2025-11-06 | -$49.92M 10-Q · filed 2025-11-06 | -$70.95M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$13.60M 10-Q · filed 2025-08-06 | -$26.57M 10-Q · filed 2025-08-06 | -$47.60M derived: sum of 3 quarters · filed 2025-08-06 | -$62.19M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$12.97M 10-Q · filed 2025-05-06 | -$34.00M derived: sum of 2 quarters · filed 2025-05-06 | -$48.59M derived: sum of 3 quarters · filed 2025-05-06 | |
| 2023-12-31 | -$21.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$35.62M derived: sum of 2 quarters · filed 2025-03-20 | -$63.86M 10-K · filed 2025-03-20 | |
| 2023-09-30 | -$14.59M 10-Q · filed 2024-11-07 | -$42.83M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |